Compare Neurocrine Biosciences Inc (NBIX) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Rigetti Computing Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B), while Rigetti Computing Inc trades at $14.02 (market cap $4.72B). The key difference: Neurocrine Biosciences Inc is far larger — about 3× Rigetti Computing Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Rigetti Computing Inc for 35 Days on average.
| NBIX | RGTI | |
|---|---|---|
Market Cap | $14.36B | $4.72B |
Volume | 1,237,180 | 17,136,381 |
Sector | Health | Technology |
52-Week High | $185.50 | $56.34 |
52-Week Low | $123.10 | $12.90 |
Typical Hold Time | 23 Days | 35 Days |
Enterprise Value | $14.37B | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
RGTI trades at $14.04, down 3.77% today, with a bearish technical signal despite bullish oscillators. The company shows minimal revenue of $7.09M in 2025 with a massive net loss of -$216.21M, resulting in negative profit margins. Analyst consensus is strongly bullish with 6 buy ratings and a $21.67 price target, representing 54% upside. Recent news highlights quantum computing sector momentum and Rigetti's hybrid quantum-HPC strategy with partners like HPE.
While analyst optimism and quantum computing potential offer significant upside, RGTI faces substantial execution risks with negative cash flow, high valuation multiples, and intense competition. The stock presents high-risk/high-reward potential for investors willing to tolerate volatility in exchange for quantum computing exposure, but requires careful monitoring of commercialization progress and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
